June 3, 2022

Sound Biologics Announces Presentations at ASCO 2022 Annual Meeting

PSB205/QL1706, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, demonstrates anti-tumor effects with acceptable tolerability and manageable toxicity

April 13, 2021

Sound Biologics Announces Proof-of-Concept Success at AARC Annual Meeting

Phase 1 Study results for PSB205, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, provides proof-of-concept and early clinical validation of the MabPair platform

April 10, 2019

Sound Biologics Announces FDA Allowance of its IND Application for PSB205, an Anti-PD-1/CTLA-4 MabPair, in Relapsed and Refractory Solid Tumors